您的位置: 首页 > 农业专利 > 详情页

Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
专利权人:
Teva Pharmaceutical Industries Ltd.
发明人:
Tarcic, Nora,Bar-Zohar, Dan,Kofler, Dina
申请号:
AU2017202055
公开号:
AU2017202055A1
申请日:
2017.03.28
申请国别(地区):
AU
年份:
2017
代理人:
摘要:
#$%^&*AU2017202055A120170420.pdf#####USE OF LAQUINIMOD FOR REDUCING FATIGUE, IMPROVING FUNCTIONAL STATUS, AND IMPROVING QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS Abstract of the Disclosure The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis human patient, comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a method for providing neuroprotection to a human subject, the method comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充